S25. COGNITIVE REMEDIATION THERAPY AND ITS EFFECTS ON BDNF SERUM LEVELS

ABSTRACT: Abstract

Background

Brain-derived neurotrophic factor (BDNF) has been proposed as a biomarker of schizophrenia and, more specifically, as a biomarker of cognitive recovery. Unfortunately, it has only been tested once with cognitive remediation treatment (CRT).

Methods

A randomized and controlled trial (NCT02341131) with 70 schizophrenia outpatients and 15 healthy volunteers was conducted. The participants with schizophrenia were randomly assigned to either CRT or the control group. All the participants were assessed in terms of cognition, quality of life, and their serum BDNF levels at both baseline and after the intervention. Additionally, comparisons of the effects of the different genotypes of the Val66Met polymorphism at the BDNF gene on the outcome variables were als

SUBMITTER: Penades R 

PROVIDER: S-EPMC5888225 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature